BioSpace News Archive

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT™ sensor and AI-based feedback platform, augmenting the BEAT™diabetes program.

AVEO Oncology, an LG Chem company, (“AVEO”), announced today that it has completed enrollment in the pivotal Phase 3 TiNivo-2 study in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure.

Theralink Technologies, Inc., a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc., announces the appointment of Faith Zaslavsky as its new Chief Executive Officer.

Phantom Neuro, the pioneering neurotech startup, announced the successful demonstration of their technology in a porcine model.

Inspired Spine, a leading innovator in minimally invasive spinal surgery, is thrilled to announce the grand opening of the state-of-the-art “Haring J Nauta” Lab.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer.

Verona Pharma plc announces the submission of a New Drug Application to the US Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.

ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced positive data from a non-human primate study.

Allecra Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections.